- Home
- STHO vs CABA Comparison
STHO vs CABA Comparison
Compare STHO & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- CABA
- Stock Information
- Founded
- STHO N/A
- CABA 2017
- Country
- STHO United States
- CABA United States
- Employees
- STHO N/A
- CABA N/A
- Industry
- STHO Real Estate
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STHO Real Estate
- CABA Health Care
- Exchange
- STHO Nasdaq
- CABA Nasdaq
- Market Cap
- STHO 117.1M
- CABA 118.8M
- IPO Year
- STHO N/A
- CABA 2019
- Fundamental
- Price
- STHO $8.57
- CABA $1.39
- Analyst Decision
- STHO
- CABA Strong Buy
- Analyst Count
- STHO 0
- CABA 8
- Target Price
- STHO N/A
- CABA $26.13
- AVG Volume (30 Days)
- STHO 107.9K
- CABA 771.7K
- Earning Date
- STHO 05-09-2025
- CABA 03-31-2025
- Dividend Yield
- STHO N/A
- CABA N/A
- EPS Growth
- STHO N/A
- CABA N/A
- EPS
- STHO N/A
- CABA N/A
- Revenue
- STHO $113,297,000.00
- CABA N/A
- Revenue This Year
- STHO N/A
- CABA N/A
- Revenue Next Year
- STHO N/A
- CABA N/A
- P/E Ratio
- STHO N/A
- CABA N/A
- Revenue Growth
- STHO N/A
- CABA N/A
- 52 Week Low
- STHO $7.96
- CABA $1.36
- 52 Week High
- STHO $14.50
- CABA $19.04
- Technical
- Relative Strength Index (RSI)
- STHO 51.53
- CABA 29.81
- Support Level
- STHO $7.97
- CABA $1.45
- Resistance Level
- STHO $8.42
- CABA $1.85
- Average True Range (ATR)
- STHO 0.35
- CABA 0.14
- MACD
- STHO 0.02
- CABA -0.01
- Stochastic Oscillator
- STHO 53.10
- CABA 4.65
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.